Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.

Lancet (London, England)·2023
Same author

EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer.

Proceedings of the National Academy of Sciences of the United States of America·2023
Same author

Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges.

British journal of cancer·2023
Same author

MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.

Cancer cell·2023
Same author

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.

The Lancet. Digital health·2023
Same author

Corrigendum to "Game of clones: Battles in the field of carcinogenesis" [Pharmacology & Therapeutics, volume 237, Pages 108-251].

Pharmacology & therapeutics·2023

Related Experiment Video

Updated: Jun 4, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Methodological and practical challenges for personalized cancer therapies.

Ignacio I Wistuba1, Juri G Gelovani, Jörg J Jacoby

  • 1Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Nature Reviews. Clinical Oncology
|March 3, 2011
PubMed
Summary

Personalized cancer medicine shows promise, but clinical trials face challenges. Novel trial designs and validated biomarkers are crucial for advancing targeted cancer therapies and improving patient outcomes.

More Related Videos

Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
07:31

Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue

Published on: May 26, 2023

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models
05:33

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Published on: September 6, 2024

Related Experiment Videos

Last Updated: Jun 4, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
07:31

Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue

Published on: May 26, 2023

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models
05:33

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Published on: September 6, 2024

Area of Science:

  • Oncology
  • Translational Medicine
  • Biomarker Discovery

Background:

  • Personalized cancer medicine, tailoring treatments to individual tumor molecular characteristics, holds significant therapeutic potential.
  • Despite the availability of targeted therapy agents, many have yielded disappointing clinical trial results, highlighting unmet needs in the field.

Purpose of the Study:

  • To propose advancements in clinical trial design and biomarker identification for personalized cancer medicine.
  • To address challenges hindering the translation of validated biomarkers from research to clinical practice.

Main Methods:

  • Recommending a new generation of clinical trials incorporating tumor biopsies for molecular analysis.
  • Advocating for novel statistical designs to enhance trial efficiency and outcome prediction.
  • Emphasizing the critical role of identifying and validating appropriate biomarkers for treatment selection.

Main Results:

  • Current biomarker strategies, often based on single gene mutations, require expansion.
  • Gene-expression signatures, protein-expression signatures, and advanced imaging technologies show future biomarker potential.
  • Existing challenges in biomarker development, regulation, and reimbursement impede clinical translation.

Conclusions:

  • Novel clinical trial designs and robust biomarker strategies are essential for realizing the potential of personalized cancer medicine.
  • Overcoming methodological, regulatory, and reimbursement hurdles is critical for the successful implementation of validated biomarkers.
  • Future efforts must focus on the rapid and reliable translation of biomarkers to improve cancer patient care.